公开(公告)号：US11957749B2

公开(公告)日：2024-04-16

申请号：US16772194

申请日：2018-12-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia Ammendola ,  Babak Bayat ,  Clarisse Lorin ,  Ventzislav Bojidarov Vassilev ,  Alessandra Vitelli

IPC: A61K39/29 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/292 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/57 ,  C07K2319/40 ,  C12N2710/10343 ,  C12N2710/24143 ,  C12N2730/10122 ,  C12N2730/10134

Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.